Piramal Pharma Limited Press Release Jan 29 2026
Filed with NSE · · 28 pages · English
Summary by 6ix AI
The report highlights challenges such as inventory destocking and slower order inflows, but also notes early signs of recovery in the biopharma sector and increased customer interest in their facilities. Additionally, the company has made significant investments to expand its capabilities and has entered into an agreement to acquire a branded injectable product, Kenalog, to enhance its portfolio. Overall, despite a challenging year, the company remains optimistic about future growth prospects and is focused on strengthening its core business areas.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Piramal Pharma
- Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Press Release Nov 05 2025
Later from Piramal Pharma
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Press Release Feb 05 2026
- Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma